G2 accumulation and melanin overproduction in malignant melanocytes treated with a new nitrosourea

Melanoma Research

Volumn 8, Issue 6, 1998, Pages 517-527

  Buchdahl, C ^a   Papon, J ^a   Communal, Y ^b   Bourges, M ^c   Madelmont, J C ^a  

^a INSERM   (France)

^b CENTRE JEAN PERRIN   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Cystemustine; Melanogenesis; Melanoma treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CYSTEMUSTINE; MELANIN; NITROSOUREA DERIVATIVE; MONOPHENOL MONOOXYGENASE; N' (2 CHLOROETHYL) N (2 (METHYLSULFONYL)ETHYL) N' NITROSOUREA; N'-(2-CHLOROETHYL)-N-(2-(METHYLSULFONYL)ETHYL)-N'-NITROSOUREA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA DAMAGE; MELANOGENESIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; ELECTRON MICROSCOPY; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; METABOLISM; PATHOLOGY; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G2 PHASE; MELANINS; MELANOMA, EXPERIMENTAL; MICE; MICROSCOPY, ELECTRON; MONOPHENOL MONOOXYGENASE; NITROSOUREA COMPOUNDS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032217289     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199812000-00007     Document Type: Article

References (47)

1. Godenèche D, Madelmont JC, Moreau MF, Duprat J, Chabard JL, Plagne R, Meyniel G. Metabolic disposition of 2-chloroethyl nitrosocarbamoylcystamine in rats. Drug Metab Disposition 1985; 13: 220-226.
2. Madelmont JC, Godenèche D, Parry D, Duprat J, Chabard JL, Plagne R, Mathé G, Meyniel G. New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results. J Med Chem 1985; 28: 1346-1350.
3. Bourrut C, Chenu E, Godenèche D, Madelmont JC, Maral R, Mathé G, Meyniel G. Cytostatic action of two nitrosoureas derived from cysteamine. Br J Pharmacol 1986; 89: 539-546.
4. Madelmont JC, Cystemustine. Drugs Future 1994; 19: 27-30.
5. Godenèche D, Madelmont JC, Labarre P, Plagne R, Meyniel G. Disposition of new sulfur-containing 2-(chloroethyl) nitrosoureas in rats. Xenobiotica 1987; 17: 59-70.
6. Roche H, Adenis L, Cure H, Fargeot P, Guiochet N, Eymard JC, Urosevic V, Lentz MA, Chevalier B, Chollet P, for the EORTC Clinical Screening Group. Phase II trial of cystemustine, a new chloroethylnitrosourea, as second line treatment of malignant gliomas. 19th ESMO Congress, Lisbon, 1994.
7. Urosevic V, Roche H, Fargeot P, Godin O, Chollet P, Lentz MA, Van Glabbeke M, Chevallier B, Fumoleau P, for the EORTC Clinical Screening Group. Results of Phase II trials with cystemustine at 90 mg/sqm in advanced malignant melanoma. 19th ESMO Congress, Lisbon, 1994.
8. Godenèche D, Labarre P, Moreau MF, Madelmont JC, Rapp M, Papon J, Veyre A. Main urinary metabolites of two cysteamine-containing 2-(chloroethyl) nitrosoureas in rats. Drug Metab Disposition 1992; 21: 93-99.
9. Ludlum DB. The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Invest 1997; 15: 588-598.
10. Laval J, Lopes F, Madelmont JC, Godenèche D, Meyniel G, Habraken Y, O'Connor TR, Boiteux S. Excision of Imidazole Ring-opened N7-Hydroxyethylguanine from Chloroethylnitrosourea Treated DNA by Escherichia coli Formamidopyrimidine DNA Glycosylase. IARC Scientific Productions, 1991: 412-416.
11. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88: 1346-1360.
12. 6-alkylguanine-DNA alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 1988; 15: 279-292.
13. 6-methylguanine-DNA methyltransferase. J Biol Chem 1994; 269: 730-733.
14. 6-alkylguanine DNA alkyltransferase. Prog Nucleic Acid Res Mol 1995; 51: 167-223.
15. Wood RD. DNA repair in eukaryotes. Annu Rev Biochem 1996; 65: 135-137.
16. Kohn KW. Interstrand cross-linking of DNA by 1,3-bis-(2-chloroethyl)-1-nitrosourea and other 1(2-haloethyl)-1-nitrosoureas. Cancer Res 1977; 77: 467-471.
17. Tong WP, Kohn KW, Ludlum DB. Modifications of DNA by different haloethylnitrosoureas. Cancer Res 1982; 42: 4460-4464.
18. Godenèche D, Rapp M, Thierry A, Laval F, Madelmont JC, Chollet P, Veyre A. DNA damage induced by a new 2-chloroethylnitrosourea on malignant melanoma. Cancer Res 1990; 50: 5898-5903.
19. 2-acetylguanosine association. Melanoma Res 1998; 8: 123-130.
20. 6-alkylguanine-DNA alkyltransferase inhibitor. Biol Cell 1996; 88: 1-2.
21. 6-alkylguanine-DNA alkyltransferase. Cell Biol Toxicol 1998; 14: 148.
22. Filder IJ. Immune stimulation-inhibition of experimental cancer metastasis. Cancer Res 1974; 34: 491-498.
23. Phillips HJ. Dye exclusion tests for cell viability. In: Krusse PF, Patterson MK, eds. Tissue Culture Methods and Applications. 1973: 406-408.
24. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye-binding. Anal Biochem 1976; 72: 248.
25. Davies EM. Proteins Assays: A Review of Common Techniques. American Biotech Laboratories, 1988: 28-37.
26. Seigrist W, Eberle AN. In situ melanin assay for MSH using mouse B16 melanoma cells in culture. Anal Biochem 1986; 159: 191-197.
27. Pomerantz SH. Tyrosinase hydroxylation catalysed by mammalian tyrosinase: an improved of method assay. Biochem Biophys Res Commun 1964; 16: 2.
28. Tobey R, Crissman HA. Comparative effects of three nitrosourea derivatives on mammalian cell cycle progression. Cancer Res 1975; 35: 460-470.
29. 2. Nature 1975; 254: 245-247.
30. Nomura K, Hoshino T, Knebel K, Deen DF, Barker M. BCNU-induced perturbations in the cell cycle of 9L rat brain tumor cells. Cancer Treat Rev 1978; 62: 747-754.
31. Hoshino T, Deen DF, Williams ME, Sano Y. Differential response of elutriated 9L cells to treatment with 1,3-bis(2-chloroethyl)-1-nitrosurea. Cancer Res 1981; 41: 4404-4407.
32. Nutt CL, Chambers AF, Cairncross JG. Wild-type p53 renders mouse astrocytes resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea despite the absence of a p53 dependent cell cycle arrest. Cancer Res 1996; 56: 2748-2751.
33. Hayes MT, Hartley J, Parsons PG. In vitro evaluation of fotemustine as a potential agent for limb perfusion in melanoma. Melanoma Res 1998; 8: 67-75.
34. Kohn KW, Jackman J, O'Connor PM. Cell cycle and cancer chemotherapy. J Cell Biochem 1994; 54: 440-452.
35. Ali-Osman F, Stein DE, Renwick A. Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. Cancer Res 1990; 50: 6976-6980.
36. Benathan M, Alvero-Jackson H, Mooy AM, Scalletta C, Frenk E. Relationship between melanogenesis glutathione levels and melphalan toxicity in human melanoma cells. Melanoma Res 1992; 2: 305-314.
37. Benathan M. Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells. Melanoma Res 1996; 6: 183-189.
38. Del Marmol V, Solano F, Sels A, Huez G, Libert A, Lejeune F, Ghanem G. Glutathione depletion increases tyrosinase activity in human melanoma cells. J Invest Dermatol 1993; 101: 871-874.
39. Eller MS, Yaar M, Gilchrest BA. DNA damage and melanogenesis. Nature 1994; 372: 413-414.
40. Eller MS, Ostrom K, Gilchrest BA. DNA damage enhances melanogenesis. Proc Natl Acad Sci USA 1996; 93: 1087-1092.
41. Yasutake H, Tsuchiya H, Sugihara M, Tomita K, Ueda Y, Tanaka M, Sasaki T. Combined effect of cisplatin and caffeine on murine B16-BL6 melanoma cells. Gan To Kagaku Ryoho 1989; 16: 2031-3038.
42. Kiguchi K, Constantinou AI, Huberman E. Genistein-induced cell differentiation and protein-linked DNA strand breakage in human melanoma cells. Cancer Commun 1990; 2: 271-278.
43. Hach B, Borovansky J, Vedralova E. Melanosome. A sophisticated organelle. Skorn Lek 1993; 94: 113-125.
44. Hill HZ. The function of melanin or six blind people examine an elephant. BioEssays 1992; 14: 49-56.
45. Urabe K, Aroca P, Tsukamoto K, Mascagna D, Palumbo A, Prota G, Hearing VJ. The inherent cytotoxicity of melanin precursor: a revision. Biochim Biophys Acta 1994; 1221: 272-278.
46. Sakai C, Kawakami Y, Law LW, Furumura M, Hearing VJ. Melanosomal proteins as melanoma-specific immune targets. Melanoma Res 1997; 7: 83-95.
47. Hendrix JD, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol 1992; 31: 458-466.